Target intelligence / Profile preview

Angiotensin II receptor type 2 (AGTR2)

Target
AGTR2
Molecular classification
G protein-coupled receptor, Receptor
01

Overview

Angiotensin II receptor type 2 (AGTR2), also known as the AT2 receptor, is a seven-transmembrane G protein-coupled receptor that belongs to the renin-angiotensin system (RAS). Unlike the closely related AT1 receptor, which mediates vasoconstriction and cellular proliferation, AGTR2 activation generally counteracts these effects by promoting vasodilation, apoptosis, anti-inflammatory, and anti-fibrotic pathways. It is highly expressed during fetal development but is scantily expressed in adult tissues, though its expression is upregulated under pathological conditions such as tissue injury, inflammation, and cardiovascular stress.

Therapeutically, AGTR2 is targeted by both agonists and antagonists depending on the clinical indication. AGTR2 agonists, such as buloxibutid (Compound 21), are being investigated for their protective, anti-fibrotic, and anti-inflammatory effects in cardiovascular, renal, and pulmonary diseases, including idiopathic pulmonary fibrosis and COVID-19-related lung injury. Conversely, AGTR2 antagonists, such as EMA401 (olodanrigan), have been developed to treat peripheral neuropathic pain and are being explored for their anti-proliferative effects in cancers like glioblastoma. However, drug development has faced challenges, notably the hepatotoxicity that led to the termination of EMA401 clinical trials, and potential teratogenic risks given the receptor's critical role in fetal development.

Other names
AT2 receptorType-2 angiotensin II receptorAT2RMRX88
02

Mechanism of action

Selective agonism of AGTR2 activates protective, anti-inflammatory, and anti-fibrotic pathways, whereas selective antagonism of AGTR2 inhibits neuropathic pain signaling and tumor cell proliferation.

03

Biological functions

Signal transductionApoptosisVasodilationCell proliferationInflammationTissue repair
04

Disease associations

Cardiovascular diseaseInflammationNeurodegenerative diseaseCancerInfectionOther
05

Safety considerations

HepatotoxicityTeratogenicityHypotensionHyperkalemiaInhibition of neurite regeneration
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

AGTR2 expression levelAGTR2 autoantibodiesUrinary albumin excretionInterleukin-6Nitric oxidecGMP

Beyond the preview

Go deeper on Angiotensin II receptor type 2 (AGTR2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Angiotensin II receptor type 2 (AGTR2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call